A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.
All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20211-030
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
-
São Paulo, Brazil, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brazil, 01232-010
- Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
-
São Paulo, Brazil, 08270-120
- CEPEC-Centro de Pesquisa Clinica
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazil, 41253-190
- Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
-
-
Pernambuco
-
Recife, Pernambuco, Brazil, 50070-460
- Multihemo Servicos Medicos S/A
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil, 14051-140
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São José do Rio Preto, São Paulo, Brazil, 15090-000
- Fundação Faculdade Regional de Medicina de São José do Rio Preto
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Clinica de la Costa Ltda.
-
-
Cesar Department
-
Valledupar, Cesar Department, Colombia, 200001
- Sociedad de Oncología y hematología del Cesar
-
-
-
-
-
Eldoret, Kenya, 30100
- International Cancer Institute
-
Nairobi, Kenya, 00100
- Gertrude's Children's Hospital
-
Nairobi, Kenya, 00100
- Kenya Medical Research Institute - Centre for Respiratory Disease Research
-
Nairobi, Kenya, 00200
- Strathmore University CREATES
-
-
Siaya County
-
Kisumu, Siaya County, Kenya, 40600
- KEMRI/CRDR Siaya Clinical Research Annex
-
-
-
-
Beirut
-
Hamra, Beirut, Lebanon
- American University of Beirut Medical Center
-
-
North Lebanon
-
Tripoli, North Lebanon, Lebanon
- Nini Hospital
-
-
-
-
-
Enugu, Nigeria, 460000
- University of Nigeria Teaching Hospital
-
Kaduna, Nigeria, 800212
- Barau Dikko Teaching Hospital/Kaduna State University
-
Kano, Nigeria, 700223
- Aminu Kano Teaching Hospital
-
Lagos, Nigeria, 100254
- Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
-
-
Cross River State
-
Calabar, Cross River State, Nigeria, 540242
- University of Calabar Teaching Hospital
-
-
Federal Capital Territory
-
Abuja, Federal Capital Territory, Nigeria, 900211
- National Hospital Abuja
-
Gwagwalada, Federal Capital Territory, Nigeria, 902101
- University of Abuja Teaching Hospital
-
-
Kaduna State
-
Zaria, Kaduna State, Nigeria, 810105
- Ahmadu Bello University Teaching Hospital
-
-
-
-
-
Muscat, Oman, 123
- Sultan Qaboos University Hospital
-
-
-
-
Southern
-
Jizan, Southern, Saudi Arabia, 82943
- Prince Mohammed bin Nasser Hospital
-
-
-
-
-
Dar es Salaam, Tanzania, 11101
- National Institute for Medical Research (NIMR)
-
-
-
-
-
Adana, Turkey (Türkiye), 01130
- Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
-
Adana, Turkey (Türkiye), 01250
- Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
-
Ankara, Turkey (Türkiye), 06430
- Hacettepe University Ihsan Dogramaci Children Hospital
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36604
- University of South Alabama Children's and Women's Hospital
-
Mobile, Alabama, United States, 36604
- Strada Patient Care Center, Pediatric Hematology
-
Mobile, Alabama, United States, 36606
- South Alabama Medical Science Foundation
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Children's Hospital
-
-
California
-
Orange, California, United States, 92868
- UC Irvine Medical Center
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- UConn-Neag Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Hospital and Health Sciences System (UI Health)
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago (UIC) Clinical Research Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute IDS Pharmacy
-
Boston, Massachusetts, United States, 02115
- Brigham And Woman's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Hospitals - Michigan Medicine
-
-
New York
-
The Bronx, New York, United States, 10461
- Jacobi Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
Durham, North Carolina, United States, 27710
- DUMC Investigational Drug Services Pharmacy
-
-
Texas
-
Houston, Texas, United States, 77030
- McGovern Medical School at UTHealth
-
Houston, Texas, United States, 77030
- UT Physicians Comprehensive Sickle Cell Center Houston
-
Houston, Texas, United States, 77030
- UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants who meet all the following criteria will be eligible for study enrollment:
-
Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
-
Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
-
Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.
-
If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
-
Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.
Exclusion Criteria:
Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:
- Female participant who is breastfeeding or pregnant.
- Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
- Participant withdrew consent from the originating inclacumab clinical study.
- Participant was lost to follow-up from the originating inclacumab clinical study.
- Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inclacumab 30 mg/kg
Inclacumab 30 mg/kg administered intravenously (IV) |
Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs. |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Annualized Rate of Vaso-occlusive Crises (VOCs)
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Number of Inpatient Hospitalization Days for a VOC
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of SCD-related Urgent Care Visits
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Time Frame: From first dose of study treatment (Day 1) up to Week 48
|
The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure. |
From first dose of study treatment (Day 1) up to Week 48
|
|
Annualized Rate of Complicated VOCs
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
|
Annualized Rate of Red Blood Cell (RBC) Transfusions
Time Frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years). |
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GBT2104-133
- 2020-005289-32 (EudraCT Number)
- C5361003 (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.